Biocon Biologics Bolstered By Goldman Sachs Investment

Deal Worth $150m Values Biocon Subsidiary At Nearly $4bn

 
• By David Wallace
  
Goldman Sachs
Goldman Sachs is investing in Biocon Biologics • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business